Health & WellnessTech

Dynaris

We set new standard in oxygen therapy; 7 patents, FDA, superior therapy, & more
Chesterfield, 
MO
Investment type:
Equity
(Priced Round)
Target raise:
$150,000
 - $1,069,800
Minimum investment:​
$300
End date:
Jan 18, 2022
Share
Share on facebook
Share on twitter
Share on linkedin
Share on email
Highlights

  • FDA 510 (K), EUA, ISO-13485 Quality System, FDA registered manufacturing in-house, Ready to go!
  • 5.9 million patients on oxygen in the U.S. alone growing to over 7 million patients in 2023.
  • Protected by 7 U.S. Patents, more pending, foreign patents pending.
  • Experienced team with a history of success, from concept through acquisition. CEO has 28 patents
Our Story

Founded in 2014, Dynaris has developed a new standard in oxygen delivery devices. Its patented and FDA Cleared Apogee and cannula are the first in a line of products designed to improve patient health, eliminate oxygen waste, reduce prescription costs, and provide a more comfortable therapeutic experience.
Our Ambition

Dynaris is aiming for sales of $300,000,000/year or more in five years. Additional product offerings are expected to grow sales significantly beyond that figure. These projections cannot be guaranteed.